Table 1.
Patient characteristics.
| BMI at start of immunotherapy | Platelet/Lymphocyte ratio at start of immunotherapy | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Variable | BMI < 22 | BMI 22–28 | BMI > 28 | PLR < 180 | PLR > 180 | |
| Median Age at Diagnosis | 66.3 | 68.2 | 67.2 | 67.4 | 67.9 | |
| Median Age at Start of Immunotherapy | 66.5 | 69.4 | 68.6 | 66.2 | 66.5 | |
| Gender (%) | Male | 14 (18.7) | 24 (32) | 11 (14.7) | 23 (30.7) | 26 (34.7) |
| Female | 11 (14.7) | 8 (10.7) | 7 (9.3) | 7 (9.3) | 19 (25.3) | |
| Smoking Status (%) | Current | 1 (1.3) | 4 (5.3) | 2 (2.7) | 3 (4) | 4 (5.3) |
| Former | 20 (26.7) | 18 (24) | 10 (13.3) | 23 (30.7) | 25 (33.3) | |
| Never | 4 (5.3) | 10 (13.3) | 6 (8) | 4 (5.3) | 16 (21.3) | |
| Histology (%) | Adenocarcinoma | 17 (22.7) | 21 (28) | 12 (16) | 21 (28) | 29 (38.7) |
| Squamous | 6 (8) | 10 (13.3) | 6 (8) | 9 (12) | 13 (17.3) | |
| Adenosquamous | 1 (1.3) | 1 (1.3) | 0 | 0 | 2 (2.7) | |
| Large Cell | 1 (1.3) | 0 | 0 | 0 | 1 (1.3) | |
| PD-L1 Tumor Proportion Score (%) | <1% | 8 (10.7) | 14 (18.7) | 7 (9.3) | 10 (13.3) | 19 (25.3) |
| 1–49% | 8 (10.7) | 5 (6.7) | 6 (8) | 8 (10.7) | 11 (14.7) | |
| 50+% | 9 (12) | 9 (12) | 4 (5.3) | 10 (13.3) | 12 (16) | |
| Missing | 5 (6.7) | 5 (6.7) | ||||
| KRAS Mutation (%) | Yes | 5 (29.4) | 5 (29.4) | 3 (17.6) | 6 (35.3) | 7 (41.2) |
| KRAS G12C | 2 (11.8) | 1 (5.9) | 1 (5.9) | 2 (11.8) | 2 (11.8) | |